Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock: Insider Bruce Cozadd Sells 6,000 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 6,000 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $215.84, for a total transaction of $1,295,040.00. Following the completion of the transaction, the director owned 339,875 shares in the company, valued at $73,358,620. This trade represents a 1.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Stock Performance

JAZZ opened at $227.32 on Friday. The company’s 50 day moving average is $229.71 and its 200 day moving average is $217.40. The company has a current ratio of 1.82, a quick ratio of 1.58 and a debt-to-equity ratio of 1.09. The company has a market cap of $14.59 billion, a price-to-earnings ratio of 77.32, a PEG ratio of 0.47 and a beta of 0.38. Jazz Pharmaceuticals PLC has a 12-month low of $128.80 and a 12-month high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, beating analysts’ consensus estimates of ($4.03) by $0.15. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The business had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.21 billion. During the same period in the prior year, the company earned $8.13 earnings per share. The firm’s revenue was up 10.4% on a year-over-year basis. On average, equities research analysts predict that Jazz Pharmaceuticals PLC will post 10.84 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on JAZZ shares. Stifel Nicolaus set a $275.00 target price on Jazz Pharmaceuticals in a report on Tuesday, August 4th. TD Cowen boosted their price target on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Wall Street Zen lowered Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 3rd. Wells Fargo & Company upped their price target on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Finally, Piper Sandler raised their price objective on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $293.45.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. USA Financial Formulas bought a new stake in shares of Jazz Pharmaceuticals during the first quarter valued at approximately $25,000. Pension & Wealth Management Advisors Inc. bought a new position in shares of Jazz Pharmaceuticals during the third quarter worth $32,000. Ameritas Advisory Services LLC bought a new position in shares of Jazz Pharmaceuticals during the second quarter worth $47,000. Westpac Banking Corp bought a new position in shares of Jazz Pharmaceuticals during the first quarter worth $51,000. Finally, Root Financial Partners LLC grew its stake in Jazz Pharmaceuticals by 42.8% during the first quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock valued at $56,000 after acquiring an additional 89 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Key Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat Q3 2026 estimates, reporting revenue of $1.24 billion versus expectations of $1.21 billion, with revenue up 10.4% year over year. The company also raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, according to the earnings coverage. Q3 earnings call summary
• Positive Sentiment: Several firms, including RBC, Barclays, Morgan Stanley and JPMorgan, issued bullish commentary or raised price targets after the results, signaling continued analyst confidence. Barclays price target coverage
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares and director Bruce Cozadd sold 6,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans; Galá retained 140,394 shares and Cozadd retained 339,875. Planned sales are less informative about executives’ current views than discretionary transactions. CEO sale filing

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.